GSK (GSK) Stock Forecast & Price Target

$38.80 +0.23 (+0.58%)

As of 11:52 AM Eastern

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
7

Buy
3

Based on 10 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 7 have given a hold rating, and 3 have given a strong buy rating for GSK.

Consensus Price Target

$43.25
11.48% Upside

According to the 10 analysts' twelve-month price targets for GSK, the average price target is $43.25. The highest price target for GSK is $47.00, while the lowest price target for GSK is $39.50. The average price target represents a forecasted upside of 11.48% from the current price of $38.80.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

GSK Analyst Ratings Over Time

Type	Current Forecast 3/25/24 to 3/25/25	1 Month Ago 2/24/24 to 2/23/25	3 Months Ago 12/26/23 to 12/25/24	1 Year Ago 3/26/23 to 3/25/24
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	3 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	3 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$43.25	$43.25	$43.25	N/A
Forecasted Upside	11.48% Upside	18.09% Upside	27.09% Upside	N/A
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Remove Ads

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Medical Companies	S&P 500
Consensus Rating Score	2.60	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	12.09% Upside	21,088.48% Upside	16.92% Upside
News Sentiment Rating	Neutral News See Recent GSK News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/12/2025	Morgan Stanley 3 of 5 stars		Initiated Coverage	Equal Weight
11/15/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Downgrade	Buy ➝ Hold
11/12/2024	Jefferies Financial Group 2 of 5 stars		Downgrade	Buy ➝ Hold	$53.00 ➝ $39.50	+8.64%
10/31/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Fernandez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/27/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/7/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hauber Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/20/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Holford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$47.00	+6.12%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Reduce

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:52 AM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, March 21, 2025. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc recently reported earnings per share of $0.59, surpassing analysts' expectations of $0.44, indicating strong financial performance and effective management.
The company has increased its quarterly dividend to $0.3932 per share, reflecting a commitment to returning value to shareholders, with an annualized yield of 3.98%.
GSK plc has received a "strong-buy" rating from analysts, suggesting positive market sentiment and potential for stock price appreciation.
The current stock price is $39.22, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
With a return on equity of 48.59%, GSK plc demonstrates efficient use of equity capital, which can be attractive to investors seeking profitable companies.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

The company's net margin stands at 8.13%, which may indicate lower profitability compared to competitors in the pharmaceutical industry.
GSK plc has a high dividend payout ratio of 98.74%, suggesting that a significant portion of earnings is distributed as dividends, potentially limiting reinvestment in growth opportunities.
Despite recent upgrades, the stock has a consensus rating of "Moderate Buy," which may imply that there are concerns about its long-term growth potential.
Institutional investors and hedge funds own only 15.74% of GSK plc's stock, which could indicate a lack of confidence from larger investors.
The stock's trading volume has been below its average, which may suggest reduced investor interest or liquidity issues.

GSK Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is $43.25, with a high forecast of $47.00 and a low forecast of $39.50.
: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 7 hold ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GSK shares.
: According to analysts, GSK's stock has a predicted upside of 11.48% based on their 12-month stock forecasts.
: GSK has been rated by research analysts at Morgan Stanley in the past 90 days.
: Analysts like GSK less than other "medical" companies. The consensus rating score for GSK is 2.60 while the average consensus rating score for "medical" companies is 2.82. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:GSK) was last updated on 3/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target